ZYDUS LIFESCIENCES LIMITED
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- -
- Established
- 1952-01-01
- Employees
- -
- Market Cap
- $13.6B
- Website
- http://cadilapharma.com
A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates
Phase 2
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Arm1Drug: Arm 2
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 24
- Registration Number
- NCT06398808
- Locations
- 🇮🇳
ICON Hospital, Ahmedabad, Gujarat, India
Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis
Phase 2
Completed
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: ZYIL1 capsules 25 mg and 50 mg PlaceboDrug: ZYIL1 capsules 50 mg and 25 mg PlaceboDrug: ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mgDrug: Matching placebo 25 mg and Matching placebo 50 mg
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 24
- Registration Number
- NCT05981040
- Locations
- 🇮🇳
Zydus Hospitals & Healthcare Research, Ahmedabad, Gujarat, India
🇮🇳Rhythm heart institute, Vadodara, Gujarat, India
🇮🇳BrainS Super Speciality Hospital, Bengaluru, Karnataka, India
A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers
Phase 1
Recruiting
- Conditions
- Falciparum MalariaAsymptomatic ConditionUncomplicated Malaria
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 36
- Registration Number
- NCT05911828
- Locations
- 🇬🇦
Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
Phase 4
Recruiting
- Conditions
- NAFLDType 2 DiabetesObesityDyslipidemiasMetabolic Syndrome
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 1500
- Registration Number
- NCT05872269
- Locations
- 🇮🇳
Gastroplus Digestive Disease Centre, Ahmedabad, India
🇮🇳Mission GastroHospital, Ahmedabad, India
🇮🇳Artemis Hospital, Gurgaon, India
A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)
Phase 4
Recruiting
- Conditions
- Chronic Kidney DiseasesAnemia of Chronic Kidney Disease
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 1004
- Registration Number
- NCT05515367
- Locations
- 🇮🇳
Indira Gandhi Institute of Medical Sciences, Sheikhpura, Bihar, India
A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)
Phase 3
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- Biological: Pertuzumab (Perjeta®)Biological: Pertuzumab (ZRC-3277)
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 268
- Registration Number
- NCT05283837
- Locations
- 🇮🇳
Unique Hospital-Multispeciality & Resesarch Institute, Sūrat, India
A Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 24
- Registration Number
- NCT05206201
- Locations
- 🇮🇳
Zydus Research Centre, Ahmedabad, Gujarat, India
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)
Phase 2
Completed
- Conditions
- Cryopyrin Associated Periodic Syndrome
- Interventions
- Drug: ZYIL1 capsule
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 3
- Registration Number
- NCT05186051
- Locations
- 🇦🇺
Department of Clinical Immunology and Allergy, Adelaide, Australia
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ZYIL1 Capsule
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 18
- Registration Number
- NCT04972188
- Locations
- 🇮🇳
Zydus Research Centre, Ahmedabad, Gujarat, India
Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ZYIL1 capsule
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 30
- Registration Number
- NCT04731324
- Locations
- 🇮🇳
Zydus Research Centre, Ahmedabad, Gujarat, India